BOARD OF DIRECTORS

Upon [**REDACTED**], our Board will comprise 12 Directors, including six executive Directors, two non-executive Directors and four independent non-executive Directors. Our Directors serve a term of three years and may be re-elected for successive re-appointments. The independent non-executive Directors shall not hold office for more than six consecutive years pursuant to the relevant PRC laws and regulations.

The table below sets out certain information of our Directors.

Name	Age	Position	Time of appointment as Director	Time of joining our Group	Responsibilities
Executive Directors					
Dr. DING Lieming (丁列明)	62	Chairman of the Board, executive Director, General Manager and Chief Executive Officer	August 2013	January 2003	Overall strategic planning, decision-making, business direction, operational management
Mr. WAN Jiang (萬江)	57	Executive Director, Senior Vice President and President of Global Sales	March 2017	April 2011	In charge of overseeing the Group's global commercialization strategy and operations
Prof. LI MAO	69	Executive Director, President of R&D and Chief Medical Officer	May 2025	February 2025	In charge of the Research Institute and Medical Department
Mr. DING Shizhe (丁師哲)	35	Executive Director and Assistant to the Chairman	October 2024	August 2015	In charge of the Group's program in-licensing, business development, and technology transfer initiatives
Mr. FAN Jianxun (范建勛)	55	Executive Director, Vice President and Chief Financial Officer	October 2021	August 2016	In charge of the Finance Department and Investment Department
Ms. TONG Jia (童佳)	48	Executive Director and President of Administration	January 2021	November 2003	In charge of the Chairman's Office, Human Resources Department, Securities Department, Internal Control Department, Project Application Department, Corporate Relations Office, Administration Department, and Engineering Department
Non-executive Directors					
Prof. TIAN XU	63	Non-executive Director	October 2022	October 2022	Overseeing the operational management, financial management and board affairs of our Group
Dr. Yongjun LIU	66	Non-executive Director	December 2025	December 2025	Overseeing the operational management, financial management and board affairs of our Group
Independent Non-executive Directors					
Ms. WONG Yan Ki, Angel (黃欣琪)	54	Independent Non-executive Director	January 2021	January 2021	Supervising and providing independent judgment to our Board
Ms. XIAO Jiajia (肖佳佳)	42	Independent Non-executive Director	October 2022	October 2022	Supervising and providing independent judgment to our Board
Prof. Jianwei XUAN	63	Independent Non-executive Director	December 2025	December 2025	Supervising and providing independent judgment to our Board
Prof. YE Jianliang (葉建亮)	49	Independent Non-executive Director	December 2025	December 2025	Supervising and providing independent judgment to our Board

Note:

(1) Dr. WANG Jiabing (王家炳) ("**Dr. WANG**"), a former director, senior vice president and chief scientist of our Group, served our Company from February 2016 to September 2024. He voluntarily resigned to focus on his personal arrangements. During his tenure, Dr. WANG was primarily responsible for overseeing the operations of the Research Institute and was involved at an overall and supervisory level in the Group's R&D activities. Dr. WANG has confirmed to the Board that he did not have any disagreement with the Board and that there was no matter relating to his resignation that needs to be brought to the attention of the Shareholders or the Stock Exchange. The Directors are of the view that Dr. WANG's departure does not have any material adverse impact on the Group, given that (i) the Group's overall R&D strategy and direction continue to be overseen by Dr. DING; (ii) the R&D team structure has remained substantially unchanged following Dr. WANG's departure and has continued to operate under Dr. DING's supervision; (iii) Dr. WANG's responsibilities have been assumed by other Directors and senior management; and (iv) his departure does not affect the Group's ownership of or access to its intellectual property.

Executive Directors

Dr. DING Lieming (丁列明), aged 62, has been executive Director, Chairman of the Board, general manager and chief executive officer of our Company since August 2013. Dr. DING is responsible for overall strategic planning, decision-making, business direction and operational management.

Dr. DING currently holds several directorship and senior positions in the subsidiaries of our Company. Since November 2010, he has served as a director at Beijing Beimeituo Innovative Drug Research and Development Limited (北京貝美拓新藥研發有限公司). He became a director at Betta Investment (Hong Kong) Limited in October 2014 and at Zhejiang Betta Pharmaceutical Sales Co., Ltd. (浙江貝達醫藥銷售有限公司) in April 2016. Additionally, Dr. DING has been serving as chairman of the board at Xcovery Holdings since September 2016, at Xcovery Betta Pharmaceuticals, Inc. since January 2017 and at Equinox Sciences, LLC since May 2017. He has been the Chairman of the Board of Directors of Challenge MediTech Company Ltd. (卡南吉醫藥科技(上海)有限公司) since June 2017.

Dr. DING is a national leading talent (國家領軍人才), an expert of the overall group of the National "Major New Drug Creation" Program (國家重大新藥創製專項總體組), Zhejiang Provincial Distinguished Expert (浙江省特級專家) and is a licensed physician in pathology in the United States. He has served as a deputy to the 12th and 13th National People's Congress, and a member of the 14th National Committee of the Chinese People's Political Consultative Conference. He is a standing committee member of the All-China Federation of Returned Overseas Chinese ("Returned Overseas Chinese Federation") (中華全國歸國華僑聯合會"中國僑聯"), specially appointed deputy director of the Biological and Pharmaceutical Special Committee of the Returned Overseas Chinese Federation Expert Panel (中國僑聯專家委員會生物與醫藥專委會), vice chairman of the Zhejiang Federation of Returned Overseas Chinese (浙江省歸國華僑聯合會), director of the Economic Work Committee of the Chinese Peasants and Workers Democratic Party Central Committee and concurrently director of its Economic and Financial Branch (中國農工民主黨中央經濟工作委員會主任兼經濟金融分會主任), deputy chairman of the Zhejiang Committee of the Chinese Peasants and Workers Democratic Party (中國農工民主黨浙江省委會), vice president of the China Pharmaceutical Innovation and Research Development Association (中國醫藥創新促進會) and president of the Zhejiang Pharmaceutical Industry Association (浙江省醫藥行業協會).

In 2003, Dr. DING founded Betta Pharmaceuticals and successfully spearheaded the development of groundbreaking therapies including China's first small-molecule lung cancer targeted therapy Conmana®, the nation's first ALK targeted drug Ensacove®, the pioneering renal cancer treatment Vorolanib, etc. Through these achievements, he established a domestically leading platform for innovative drug research, development and commercialization. And has fostered Betta innovation ecosystem to incubate multiple disruptive breakthrough projects. He has led or participated in 13 projects under the National "Major New Drug Creation" Science and Technology Major Project (國家"重大新藥創製"科技重大專項項目), filed 307 patent applications, and published 61 academic papers. Due to his outstanding contributions, he has received numerous honors, including the First Prize of the National Science and Technology Progress Award (國家科學技術進步獎) (as the lead author), the China Patent Gold Award (中國專利金獎), the China Industrial Grand Award (中國工業大獎), the National Award for Innovation and Advancement (全國創新爭先獎狀), the National Outstanding Professional and Technical Talent Award (全國傑出專業技術人才), the National Outstanding Science and Technology Worker Award (全國優秀科技工作者), the "Top Ten" of the Chinese Overseas Community (中國僑界"十傑"), and the Zhejiang Major Contribution Award in Science and Technology (浙江省科技重大貢獻獎).

Dr. DING obtained his bachelor's degree and master's degree in medicine from Zhejiang Medical University (浙江醫科大學) (currently known as Zhejiang University School of Medicine (浙江大學醫學院)) in the PRC in August 1984 and July 1989, respectively. Dr. DING was a senior researcher at the Oncology Center of the University of Arkansas for Medical Sciences from 1992 to 1996. From 1996 to 2002, Dr. DING passed the examination and certification of the Educational Commission for Foreign Medical Graduates (ECFMG) and completed the full course of study and training as a pathology resident at the Department of Pathology, University of Arkansas for Medical Sciences in the United States.

Mr. WAN Jiang (萬江), aged 57, has been an executive Director of our Company since March 2017. Mr. Wan joined our Group in April 2011 and has been a vice president of our Company since 2013, senior vice president of our Company since February 2016 and president of global sales of our Company since February 2026. Mr. Wan has been serving as a director of Anew Pharmaceuticals since May 2017, a manager of Betta Pharmaceutical S&T since December 2021, and a director of Beta-Anjin Pharmaceutical Co., Ltd. (貝達安進製藥有限公司) since January 2022. Mr. Wan is in charge of overseeing the Group's global commercialization strategy and operations.

Mr. Wan has 30 years of experience in drug promotion channel building and drug accessibility enhancement and possesses significant professional influence in the application of oncology therapeutics within the Chinese market. Prior to joining our Group, Mr. Wan had worked at the department of orthopedics at Beijing Tongren Hospital (北京同仁醫院) beginning in 1992 and has served in senior management positions at renowned medical institutions and pharmaceutical companies including Bristol-Myers Squibb (BMS) in the United States, Rhone-Poulenc Rorer in France (subsequently merged into Sanofi-Aventis, now Sanofi), Eli Lilly in the United States, AstraZeneca in the United Kingdom and Merck Sharp & Dohme in the United States from 1995 to 2011.

Mr. Wan obtained his bachelor's degree in clinical medicine from Capital Medical University (首都醫科大學) in the PRC in July 1992 and obtained a master's degree of Business Administration for Senior Executives from the Hong Kong University of Science and Technology (香港科技大學) in Hong Kong in June 2007.

Prof. LI MAO, aged 69, has been an executive Director of our Company since May 2025. Prof. Mao was appointed as president of R&D, chief medical officer of our Company in February 2025 and is in charge of the Research Institute and Medical Department. Previously, he served as senior vice president and chief medical officer of our Company and the general manager of Challenge MediTech Company Ltd. (卡南吉醫藥科技(上海)有限公司) from April 2018 to March 2021.

Prof. Mao is a tenured professor at The University of Texas MD Anderson Cancer Center (美國德克薩斯大學安德森癌症中心) and a Changjiang Scholar Distinguished Visiting Professor at the School of Medicine of Shanghai Jiao Tong University (上海交通大學醫學院). Prior to joining our Group, he formerly served as chairman of the department of oncology and diagnostic sciences at the University of Maryland in the United States and as vice president of the Lung Cancer Center at Johnson & Johnson. He possesses over 35 years of clinical practice experience in the field of oncology, along with extensive experience in enterprise-level pharmaceutical product research and clinical development management. He has published over 200 SCI papers in top-tier international academic journals, with his work cited more than 30,000 times in total.

Prof. Mao obtained his bachelor's degree in clinical medicine from Nanjing Medical University (南京醫學院) (currently known as Nanjing Medical University (南京醫科大學)) in December 1982. He received a postdoctoral degree from the Johns Hopkins University School of Medicine in the United Sates in June 1995.

Mr. DING Shizhe (丁師哲), aged 35, was appointed as an executive Director in October 2024 and was elected as an employee representative Director in December 2025. Mr. Ding joined the Company in August 2015, and has held various positions including strategic cooperation specialist, strategic cooperation manager, deputy director and director of our Company. Mr. Ding served as executive deputy general manager of Betta Dreamworks (貝達夢工場) from August 2020 to January 2022. Since January 2022, he has served as assistant to the Chairman of the Board. Mr. Ding has been serving as a Director at Beida Anjin (Zhejiang) Pharmaceutical Co., Ltd. (貝達安進(浙江)製

藥有限公司) since October 2021 and at Challenge MediTech Company Ltd. (卡南吉醫藥科技(上海)有限公司) since November 2024. Mr. Ding is in charge of the Group's program in-licensing, business development, and technology transfer initiatives.

Mr. Ding successfully advanced projects such as MCLA-129 and ensartinib, and established strategic cooperation agreements with InventisBio Co., Ltd. (益方生物科技(上海)股份有限公司) and Agenus Inc., a company listed on the Nasdaq Stock Exchange (stock code: AGEN). He promoted cooperation between the Company and leading enterprises both domestically and internationally, expanded the Company's product pipeline, and accelerated its internationalization process. He has participated in numerous high-quality equity investments or merger and acquisition projects, and led the equity investment in Xcovery Holdings, a U.S.-based company specializing in the research and development of anti-tumor targeted drugs. He possesses extensive experience in business communication, personnel management, and project advancement.

Mr. Ding obtained his bachelor's degree of science in biochemistry, economics, and philosophy from St. Louis University in the United States in May 2015, possessing an interdisciplinary academic background in both biochemistry and philosophy.

Mr. FAN Jianxun (范建勛), aged 55, was appointed as our executive Director in October 2021. Mr. Fan served as the investment director of the Company from August 2016 to July 2018, and served as the chief financial officer of the Company from March 2017 to July 2018. He has been a vice president of our Company since July 2018 and chief financial officer of our Company since March 2020. Mr. Fan is in charge of the company's Finance Department and Investment Department.

Mr. Fan is responsible for overseeing the development of the Betta Innovation Ecosystem. He brings more than 20 years of management experience in the financial industry, with deep, hands-on expertise spanning financial management, corporate finance, and industrial capital management. Since his joining, Mr. Fan has established a finance strategy centered on value creation, built a comprehensive financial management system, while driving the digital transformation of our financial functions. He has also led investments in over 30 domestic and overseas biopharmaceutical innovation projects, including the investment in Healthgen, and spearheaded numerous ecosystem collaborations under various deal structures. Since December 2017, he has served as an executive director and general manager of Betta Dream Factory (Hangzhou) Innovation Technology Co., Ltd. (貝達夢工場(杭州)創新科技有限公司). Since December 2017, he has served as an executive director and general manager of Betta Dream Factory Holdings Limited (貝達夢工場控股有限公司). Since August 2020, he has served as an executive director and general manager of Betta Dream Works (Zhejiang) Pharmaceuticals Holdings Co., Ltd. (貝達夢工場(浙江)醫藥控股有限公司).

He possesses outstanding capabilities in business and financial management, as well as investment and financing, and has strong skills in communication, coordination, and team management. He has led or participated in numerous high-quality equity investment or merger and acquisition projects. Prior to joining our Company, he served as the president of China Construction Bank Corporation, Hangzhou Xiaoshan Branch (中國建設銀行股份有限公司杭州蕭山分行) (中國建設銀行) from 2005 to 2011 and Shanghai Pudong Development Bank (上海浦東發展銀行) from 2014 to 2016.

Mr. Fan obtained his bachelor's degree in law from Nanjing Army Command College (南京陸軍指揮學院) in the PRC in December 2004, master's degree in business administration from the Macau University of Science and Technology (澳門科技大學) in the PRC in August 2006 and another master' degree in accountancy from The Chinese University of Hong Kong (香港中文大學) in the PRC in March 2023. Mr. Fan was honored with the "2025 Brand Figures · Outstanding CFO (2025年度品牌人物·傑出CFO)".

Ms. TONG Jia (童佳), aged 48, was appointed as an executive Director in January 2021. Ms. Tong is in charge of the Chairman's Office, Human Resources Department, Securities Department, Internal Control Department, Project Application Department, Corporate Relations Office, Administration Department, and Engineering Department.

Since joining our Company in 2003, Ms. Tong has held a number of key management positions, she served as the administrative director from August 2013 to February 2016, as the vice president from February 2016 to March 2020, and has been serving as the president of administration since March 2020. She also concurrently held the position of secretary of the Board of Directors of the Company from August 2013 to September 2020. Besides, Ms. Tong has served as supervisor of Zhejiang Betta Diagnostic Technology Limited (浙江貝達診斷技術有限公司) since December 2016 and as supervisor of Challenge MediTech Company Ltd. (卡南吉醫藥科技(上海)有限公司) since June 2017. Ms. Tong fully participated in and witnessed the company's development journey, established the company's operation system and mechanisms, and played a leadership role in advancing major projects such as the company's [**REDACTED**] application, applications for national-level awards, product launches, development of talent teams and construction of manufacturing bases, accumulating rich experience in corporate operation and management. Ms. Tong has also made remarkable achievements in brand building in the capital market, she was awarded the "Golden Secretary to the Board" by Sina Finance (新浪財經上市公司"金牌董秘") in July 2017 and the "Golden Bull Best Secretary to the Board award in 2017" (2017年度金牛最佳董秘) by China Security Journal (中國證券報) in November 2018. Ms. Tong served as an standing committee member of the 8th Session of the Secretary-General Committee of Zhejiang Listed Companies Association (浙江上市公司協會第八屆董秘專委會常務委員) from 2019 to 2023, and has earned wide recognition for her professional performance.

Ms. Tong obtained her executive master's degree of business administration from Zhejiang University (浙江大學) in the PRC in September 2014.

Non-executive Directors

Prof. TIAN XU, aged 63, was appointed as a non-executive Director of our Company in October 2022. Prof. Xu is responsible for overseeing the operational management, financial management and board affairs of our Group.

Prof. Xu is currently a professor at Westlake University (西湖大學) and an adjunct professor at the department of genetics at Yale University. From October 1993 to March 2018, held various positions at Yale University in the fields of genetics and neurobiology, including assistant professor, associate professor, tenured professor, C.N.H. Long Professor of Genetics, deputy chair of the genetics department, and advisor to the president. From July 1997 to March 2018, he served as a researcher at the Howard Hughes Medical Institute and concurrently as an adjunct professor, Changjiang Chair Professor (長江講座教授), director of the Developmental Biology Research Institute (發育生物學研究所), and director of the National Development and Disease International Cooperation Research Center (國家發育與疾病國際合作研究中心) at Fudan University.

Prof. Xu obtained his bachelor's degree of science in biology from Fudan University (復旦大學) in the PRC in July 1982, his Ph.D. of science in biology from Yale University in the United States in June 1990 and a post-doctoral degree from the University of California, Berkeley in the United States in September 1993.

Dr. Yongjun LIU, aged 66, was appointed as a non-executive Director of our Company in December 2025. Dr. Liu is responsible for overseeing the operational management, financial management and board affairs of our Group.

Prior to joining our Group, Dr. Liu served as senior vice president and chief scientific officer of MedImmune, a subsidiary of AstraZeneca (NASDAQ: AZN) from January 2014 to April 2016. He then served as global head of research at Sanofi (NASDAQ: SNY, EPA: SAN) from April 2016 to September 2020, and as president of Innovent Biologics, Inc. (a company listed on the Hong Kong Stock Exchange, stock code: 1801) from October 2020 to August 2024. Dr. Liu has been serving as the chairman of Parr Biotechnology (Hebei) Co., Ltd. (華普生物技術(河北)股份有限公司) since December 2024, the chairman of Suzhou Xiaolu Biotechnology Co., Ltd. (蘇州小路生物科技有限公司) since January 2025, and the chairman of Hefei Tuosheng Pharmaceutical Technology Co., Ltd. (合肥拓勝醫藥科技有限公司) since July 2025.

Dr. Liu served as chief scientist at Schering-Plough and the DNAX Research Institute from September 1991 to September 2001. He also served as the chair of the Department of Immunology and founding director of the Center for Cancer Immunology Research at The University of Texas MD Anderson Cancer Center, as well as the chief scientific officer and president of Baylor Research

Institute from October 2011 to December 2013. Dr. Liu has published over 260 scientific papers in leading academic journals such as Nature and Science, with total citations exceeding 100,000. He discovered key immunological targets including TSLP, OX40 and CD40, and led the development of multiple first-generation and second-generation innovative therapies for systemic lupus erythematosus, asthma and atopic dermatitis.

Dr. Liu obtained a bachelor's degree in medicine from Bethune Medical University (白求恩醫科大學, now known as Bethune School of Medicine of Jilin University (吉林大學白求恩醫學部)) in the PRC in August 1984 and obtained his Ph.D. degree in immunology from the University of Birmingham in the United Kingdom in July 1990.

Independent Non-executive Directors

Ms. WONG Yan Ki, Angel (黃欣琪), aged 54, was appointed as an independent non-executive Director of our Company in January 2021. Ms. Wong is responsible for supervising and providing independent judgment to our Board.

Ms. Wong has served as a director of various public companies listed in different regions. From August 2009 to January 2011, she acted as a non-executive director of Esmart Holdings Limited (currently known as Duty Free International Limited), a company listed on The Stock Exchange of Singapore Dealing and Automated Quotation System (stock code: Duty Free), during which she acted as the chairman of the board from February 2010 to January 2011. Ms. Wong served as an independent non-executive director of (i) China Best Group Holding Limited (國華集團控股有限公司, currently known as Hong Kong Robotics Group Holding Limited (港仔機器人集團控股有限公司)), a company listed on the Hong Kong Stock Exchange (stock code: 0370), from June 2011 to September 2014; (ii) Oriental Unicorn Agricultural Group Limited (東麒農業集團有限公司) (currently known as China Demter Financial Investments Limited (國農金融投資有限公司)), a company listed on the GEM of the Hong Kong Stock Exchange (stock code: 8120), from October 2011 to May 2013; (iii) China Public Procurement Limited (中國公共採購有限公司) (currently known as Cherish Sunshine International Limited (輝耀國際有限公司)), a company listed on the Hong Kong Stock Exchange (stock code: 1094), from December 2015 to July 2018, (iv) Miko International Holdings Limited (米格國際控股有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 1247), July 2017 to July 2018; (v) Yuhua Energy Holdings Limited (裕華能源控股有限公司) (currently known as Jintai Energy Holdings Limited (金泰能源控股有限公司)), a company listed on the Hong Kong Stock Exchange (stock code: 2728), from November 2016 to December 2018 and (vi) Hengxing Gold Holding Company Limited (恆興黃金控股有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 2303), and delisted by way of privatization in February 2021, from March 2013 to February 2021, respectively. From August 2014 to September 2015, she served as an independent non-executive director of China Shengda Packaging Group Inc. (中國勝達包裝集團有限公司), a company listed on the Nasdaq Stock Exchange (stock code: CPGI). Ms. Wong has been an independent director of BIT Mining Limited (formerly known as 500.com Limited), a company listed on the New York Stock Exchange (stock code: BTCM) from November 2015 to April 2023. Ms. Wong has been an independent non-executive director of Many Idea Cloud Holdings Limited (多想雲控股有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 6698), from October 2022 to June 2025, at Sino-Synergy Hydrogen Energy Technology (Jiaxing) Co., Ltd. (國鴻氫能科技(嘉興)股份有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 9663) since December 2023, at Henan Jinyuan Hydrogenated Chemicals Co., Ltd. (河南金源氫化化工股份有限公司), a company listed on the Hong Kong Stock Exchange (stock code: 2502), since October 2023 and at ALPHAMAB ONCOLOGY (康寧傑瑞生物製藥), a company listed on the Hong Kong Stock Exchange (stock code: 9966), since June 2025.

Ms. Wong obtained a bachelor of economics in international accounting, from Xiamen University (廈門大學) in July 1994, a post-graduate certificate in professional accounting from the City University of Hong Kong in November 2000 and an executive master degree of business administration from Cheung Kong Graduate School of Business (長江商學院) in the PRC in October 2009. Ms. Wong obtained the certificate of follow-up training courses for independent directors of listed companies from the Shenzhen Stock Exchange in the PRC in May 2022 and September 2024. Ms. Wong obtained the Training Certificate for Independent Directors from the Shanghai Stock Exchange in the PRC in May 2012. Ms. Wong has been admitted as a member or fellow member of several associations. Ms. Wong has been successively admitted as fellow member

of the Institute of Financial Accountants in the United Kingdom since October 2003, fellow member of the Society of Registered Financial Planners in Hong Kong since November 2003, member of the Hong Kong Institute of Directors since November 2014, fellow member of the Institute of Public Accountants (FIPA) (澳洲公共會計師協會資深會員) since April 2015, founding member of the Hong Kong Independent Non-executive Director Association (香港獨立非執行董事協會) since January 2016, fellow member of CPA Australia (澳洲會計師公會) since May 2017, member of the Guangdong Association of Management Accountants since December 2017, member of the Association of Chinese Internal Auditors in Hong Kong (香港華人內部審計師公會) since 2022 and member of CPA Australia since June 2024, respectively.

Ms. XIAO Jiajia (肖佳佳), aged 42, was appointed as an independent non-executive Director of our Company in October 2022. Ms. Xiao is responsible for supervising and providing independent judgment to our Board.

Ms. Xiao served as a partner at Beijing GuanTaoZhongMao (Hangzhou) Law Firm (北京觀韜中茂(杭州)律師事務所), and since March 2024, she has been a partner at Beijing JingTian & GongCheng (Hangzhou) Law Firm (北京競天公誠(杭州)律師事務所). Ms. Xiao has previously served as the lead counsel at Zhejiang Kaimai Law Firm (浙江凱麥律師事務所). She has been serving as an independent director at YinDu Catering Equipment Co., Ltd. (銀都餐飲設備股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 603277) since May 2024 and at Zhejiang Jinlian Technology Co., Ltd. (浙江金連接科技股份有限公司) since October 2022.

Ms. Xiao obtained her bachelor's degree in civil and commercial law from Zhejiang University of Finance and Economics (浙江財經大學) in the PRC in September 2004 and master's degree in law from the University of Sheffield in the UK in November 2005.

Prof. Jianwei XUAN, aged 63, was appointed as an independent non-executive Director of our Company in December 2025. Prof. Xuan is responsible for supervising and providing independent judgment to our Board.

Prof. Xuan has over 40 years of experience in health economics, market access and pharmaceutical policy. Prof. Xuan worked at the Pharmaceutical and Medical Device Administration Division of the Shanghai Municipal Health Bureau (上海市衛生局藥政醫療器械管理處) from July 1984 to February 1990. He then worked at GlaxoSmithKline (NYSE: GSK) from December 1994 to December 2003, with his last position as global head and director of the oncology business department. Prof. Xuan subsequently served as senior director of market access and health economics for the Asia-Pacific region and China at Pfizer (NYSE: PFE) from December 2003 to February 2014.

Prof. Xuan has been serving as the director and professor of the Institute of Pharmaceutical Economics at the School of Pharmaceutical Sciences of Sun Yat-sen University since December 2014, and as an adjunct professor at Fudan University since July 2013. He has also been serving as an independent non-executive director of Chemclin Diagnostics Co., Ltd. (科美診斷技術股份有限公司) (a company listed on the STAR Market of the Shanghai Stock Exchange, stock code: 688468) since September 2025.

Prof. Xuan obtained a bachelor's degree in pharmaceutical sciences from Shanghai First Medical College (上海第一醫學院) in the PRC in July 1984. He obtained a master's degree in pharmaceutical marketing management and a doctorate degree from the University of North Carolina in the United States in May 1992 and December 1994, respectively.

Prof. YE Jianliang (葉建亮), aged 49, was appointed as an independent non-executive Director of our Company in December 2025. Prof. Ye is responsible for supervising and providing independent judgment to our Board.

Prof. Ye has been serving as a professor and doctoral supervisor at the Department of Economics of the School of Economics at Zhejiang University (浙江大學經濟學院經濟學系) since December 2020, as a member of the Party Committee since June 2022, and as head of the Department of Economics since March 2024, respectively. Prof. Ye has concurrently been serving as the executive deputy director of the Yangtze River Delta Integration Development Research Center of Zhejiang University (浙江大學長三角一體化發展研究中心) since May 2019, and as a specially appointed researcher of the National High-end Think Tank — Regional Coordinated

Development Research Center of Zhejiang University (國家高端智庫—浙江大學區域協調發展研究中心) since September 2020. Prof. Ye has long been engaged in research in industrial economics, regional economics and institutional economics, and has led a number of major research projects funded by the National Social Science Fund of China and the Ministry of Education, with several policy research outcomes adopted by relevant government authorities. Prof. Ye has also been serving as an external director of certain municipal state-owned enterprises under the Hangzhou State-owned Assets Supervision and Administration Commission since December 2022.

Prof. Ye obtained a bachelor's degree in economics and a doctorate degree in political economy from Zhejiang University (浙江大學) in the PRC in June 1999 and June 2004, respectively. He was a visiting scholar at Queen's University in Canada from August 2014 to August 2015.

SENIOR MANAGEMENT

Upon the [**REDACTED**], our senior management will comprise five members. The table below sets out certain information of our senior management.

Name	Age	Position	Time of appointment as senior management	Time of joining our Group	Responsibilities
Dr. DING Lieming (丁列明)	62	Chairman of the Board, General Manager and Chief Executive Officer	August 2013	January 2003	Overall strategic planning, decision-making, business direction, operational management
Mr. WAN Jiang (萬江)	57	Senior Vice President and President of Global Sales	August 2013	April 2011	In charge of overseeing the Group's global commercialization strategy and operations
Prof. LI MAO	69	President of R&D and Chief Medical Officer	February 2025	February 2025	In charge of the Research Institute and Medical Department
Mr. FAN Jianxun (范建勛)	55	Vice President and Chief Financial Officer	July 2018	August 2016	In charge of the Finance Department and Investment Department
Ms. TONG Jia (童佳)	48	President of Administration	August 2013	November 2003	In charge of the Chairman's Office, Human Resources Department, Securities Department, Internal Control Department, Project Application Department, Corporate Relations Office, Administration Department, and Engineering Department

For the biographical details of Dr. DING Lieming, Mr. WAN Jiang, Prof. LI MAO, Mr. FAN Jianxun and Ms. TONG Jia, see "— Board of Directors" in this section.

INTERESTS OF OUR DIRECTORS AND SENIOR MANAGEMENT

Save as otherwise disclosed in this document, to the best knowledge, information and belief of our Directors having made all reasonable enquiries, as of the Latest Practicable Date:

(i) none of our Directors and senior management has held any other directorship in any public company the securities of which are listed on any securities market in Hong Kong or overseas during the three years immediately preceding the date of this document;

(ii) Mr. DING Shizhe is the son of Dr. DING Lieming. Save for that, none of our Directors and senior management was related to other Directors and senior management;

(iii) save as disclosed in "Appendix V — Statutory and General Information — 3. Further Information about Our Directors and Substantial Shareholders — A. Interests and short positions of our Directors and chief executive of our Company in the Shares, underlying

Shares and debentures of our Company and our associated corporations," none of our Directors and chief executive held any interest in the shares and underlying shares of our Company and our associated corporations which should be disclosed pursuant to Part XV of the SFO; and

(iv) there was no other matter with respect to the appointment of our Directors that needs to be brought to the attention of our Shareholders, and there was no information relating to our Directors that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules.

CONFIRMATION FROM OUR DIRECTORS

Each of our Directors confirms that as of the Latest Practicable Date, he or she did not have any interest in a business which competes or is likely to compete, either directly or indirectly, with our business which would require disclosure under Rule 8.10 of the Listing Rules. From time to time our non-executive Directors may serve on the boards of both private and public companies within the broader healthcare industry. However, as our non-executive Directors are not members of our executive management team and not involved in the daily operation of our Group, we do not believe that their interests in such companies as directors would render us incapable of carrying on our business independently from such other companies in which our non-executive Directors may hold directorships from time to time.

Each of our Directors confirms that he or she (i) has obtained the legal advice referred to under Rule 3.09D of the Listing Rules on September 23, 2025 and August 24, 2026, and (ii) understands his or her obligations as a director of a [**REDACTED**].

Each of our independent non-executive Directors has confirmed (i) his/her independence as regards each of the factors referred to in Rule 3.13(1) to (8) of the Listing Rules, (ii) he/she had no past or present financial or other interest in the business of our Company or our subsidiaries or any connection with any core connected person of our Company as of the Latest Practicable Date, and (iii) that there have been no other factors that might affect his/her independence at the time of his/her appointment.

EMOLUMENT OF DIRECTORS AND SENIOR MANAGEMENT

We offer our executive Directors and senior management members, who are also employees of our Company, emolument in the form of salaries, allowances, bonuses and benefits in kind. Our independent non-executive Directors receive emolument based on their responsibilities (including being members or chairman of Board committees).

For the years ended December 31, 2023, 2024, 2025 and the six months ended June 30, 2026, the aggregate amount of emolument (excluding share-based payments) paid by our Company to our Directors were RMB12.0 million, RMB9.5 million, RMB10.2 million and RMB6.4 million, respectively. It is estimated that under the arrangements currently in force, the aggregate emolument (excluding any possible payment of discretionary bonus and share-based payments) payable to our Directors for the year ending December 31, 2026, will be RMB12.9 million. For details of the remuneration of our Directors, see Note 8 to the Accountants' Report set out in Appendix I to this document.

For the years ended December 31, 2023, 2024, 2025 and the six months ended June 30, 2026, the aggregate amount of emolument (excluding share-based payments) paid by our Company to the five highest paid individuals were RMB14.0 million, RMB12.6 million, RMB12.6 million and RMB6.3 million, respectively.

During the Track Record Period, no remuneration was paid by our Company to, or receivable by, our Directors or the five highest paid individuals as an inducement to join or upon joining our Company or as a compensation for loss of office in connection with the management of the affairs of our Company or any subsidiary during the Track Record Period.

During the Track Record Period, none of our Directors waived or agreed to waive any emolument. Except as disclosed above, no other payments have been paid, or are payable, by our Company or any of our subsidiaries to our Directors or the five highest paid individuals during the Track Record Period.

COMPANY SECRETARY

Mr. TSANG Chun Ho (曾俊豪) was appointed as a joint company secretary of our Company in September 2025 with effect from the [**REDACTED**].

Mr. Tsang is an assistant manager of Company Secretarial Services of Tricor Services Limited (a member of Vistra Group). He is responsible for providing professional corporate services to listed companies in Hong Kong and has over 11 years of experience in corporate secretarial work. Mr. Tsang is a associate member of The Hong Kong Chartered Governance Institute and the Chartered Governance Institute of the United Kingdom. In 2021, he obtained a Master's Degree in Corporate Governance from the Hong Kong Polytechnic University.

CORPORATE GOVERNANCE

We have established five Board committees, namely the Strategy Committee, Audit Committee, the Nomination Committee, the Sustainability Committee and the Remuneration and Appraisal Committee. Our Board committees operate in accordance with the terms of reference established by our Board.

Audit Committee

We have established the Audit Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and paragraph D.3 of the Corporate Governance Code. The Audit Committee consists of Ms. WONG Yan Ki, Angel, Ms. XIAO Jiajia, Prof. YE Jianliang and Dr. Yongjun LIU, with Ms. WONG Yan Ki, Angel serving as the chairperson.

Nomination Committee

We have established the Nomination Committee with written terms of reference in compliance with Rule 3.27A of the Listing Rules and paragraph B.3 of the Corporate Governance Code. The Nomination Committee consists of Ms. XIAO Jiajia, Prof. Jianwei XUAN and Dr. DING with Ms. XIAO Jiajia serving as the chairperson.

Remuneration and Appraisal Committee

We have established the Remuneration and Appraisal Committee with written terms of reference in compliance with Rule 3.25 of the Listing Rules and paragraph E.1 of the Corporate Governance Code. The Remuneration Committee consists of Prof. Jianwei XUAN, Prof. TIAN XU, Ms. WONG Yan Ki, Angel and Prof. YE Jianliang, with Prof. Jianwei XUAN serving as the chairperson.

Strategy Committee

We have established the Strategy Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and paragraph D.3 of the Corporate Governance Code. The Strategy Committee consists of Dr. DING Lieming, Mr. WAN Jiang, Prof. LI MAO, Mr. DING Shizhe, Mr. FAN Jianxun and Ms. TONG Jia, with Dr. DING Lieming serving as the chairperson.

Sustainability Committee

We have established the Sustainability Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and paragraph D.3 of the Corporate Governance Code. The Strategy Committee consists of Prof. YE Jianliang, Prof. Jianwei XUAN, Mr. FAN Jianxun and Ms. TONG Jia, with Prof. YE Jianliang serving as the chairperson.

Corporate Governance Code

Our Company is committed to achieving high standards of corporate governance with a view to safeguarding the interests of our Shareholders. To accomplish this, our Company intends to comply with the Corporate Governance Code after the [**REDACTED**] save for the matter disclosed below.

Pursuant to code provision C.2.1 in Part 2 of the Corporate Governance Code, companies listed on the Hong Kong Stock Exchange are expected to comply with, but may choose to deviate from, the requirement that the roles of chairman and chief executive should be separate and should not be performed by the same individual. We do not have separate chairman of our Board and CEO, and Dr. DING currently performs these two roles. Our Board believes that vesting the roles of both the chairman of our Board and CEO in the same person has the benefit of ensuring consistent leadership within our Group and enabling more effective and efficient overall strategic planning and execution of strategic initiatives for our Group. Our Board considers that the balance of power and authority for the present arrangement will not be impaired, and this structure will enable our Company to make and implement decisions promptly and effectively.

Diversity Policy

We are committed to promoting diversity within our Company to the extent practicable by taking into consideration a number of factors in respect of our corporate governance structure. We have adopted a diversity policy which sets out the objective and approach for achieving and maintaining the diversity of our Board and our workforce (including senior management). In accordance with the diversity policy, we seek to achieve Board diversity by taking into account a number of factors, including but not limited to gender, age, ethnicity, culture and educational background, professional experience, skills, knowledge and length of service. The ultimate selection of Board candidates will be based on merit and potential contribution to our Board having due regard to the benefits of diversity on our Board and also the specific needs of our Company without focusing on a single diversity aspect. We are also committed to promoting diversity within our workforce (including senior management) to enhance the effectiveness of our corporate governance as a whole.

As at the date of this document, our Board consists of nine male members and three female members and has a relatively wide range of ages ranging from 34 years old to 68 years old. Our Company has reviewed the membership, structure and composition of the Board, and is of the opinion that the structure of the Board is reasonable, and the experience and skills of the Directors in various aspects and fields can enable our Company to maintain high standard of operation.

COMPLIANCE ADVISOR

We have appointed Somerley Capital Limited as our Compliance Advisor pursuant to Rule 3A.19 of the Listing Rules. The Compliance Advisor will provide us with guidance and advice as to compliance with the Listing Rules and applicable laws and regulations. Pursuant to Rule 3A.23 of the Listing Rules, the Compliance Advisor will advise our Company in certain circumstances, including: (i) before the publication of any regulatory announcement, circular or financial report; (ii) where a transaction, which might be a notifiable or connected transaction, is contemplated, including share issues, sales or transfer of treasury shares and share repurchases; (iii) where we propose to use the [**REDACTED**] from the [**REDACTED**] in a manner different from that detailed in this document or where our business activities, developments or results deviate from any forecast, estimate or other information in this document; and (iv) where the Hong Kong Stock Exchange makes an inquiry to our Company under Rule 13.10 of the Listing Rules.

The term of appointment of our Compliance Advisor will commence on the [**REDACTED**] and is expected to end on the date on which our Company complies with Rule 13.46 of the Listing Rules in respect of our financial results for the first full financial year commencing after the [**REDACTED**].